Compare Medpace Holdings Inc (MEDP) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs PepsiCo, Inc. — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while PepsiCo, Inc. trades at $125.97 (market cap $174.89B). The key difference: PepsiCo, Inc. is far larger — about 10.4× Medpace Holdings Inc's market cap, and PepsiCo, Inc. pays a 4.61% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and PepsiCo, Inc. for 107 Days on average.
| MEDP | PEP | |
|---|---|---|
Market Cap | $16.82B | $174.89B |
Volume | 223,093 | 23,968,864 |
Sector | Health | Consumer Staples |
52-Week High | $630.19 | $170.44 |
52-Week Low | $393.42 | $123.64 |
Typical Hold Time | 14 Days | 107 Days |
Enterprise Value | $16.44B | $215.61B |
Dividend Yield | — | 4.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
PepsiCo (PEP) trades at $128.88, up 4.24% today, with a bearish technical signal but strong fundamentals including a 16.14 P/E ratio and 51.59% ROE. Recent quarters show consistent earnings beats, with Q3 2026 EPS of $2.34 exceeding expectations. The company maintains robust cash flow, with 2025 operating cash flow of $12.09 billion, and announced a $1.48 dividend for H2-2026. News highlights price cuts on snacks like Doritos to address consumer pushback on high prices.
The outlook is mixed: analyst consensus targets $146.77 (14% upside) with a 'Hold' bias, but technicals suggest near-term pressure. Risks include competitive pricing pressures and debt levels, while opportunities lie in margin recovery and North American turnaround efforts. The stock offers value with a reasonable valuation and dividend yield, but requires monitoring of volume trends post-price adjustments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
